Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Lymphoid 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Neuroblastoma 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Cancer Pain 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Bevacizumab 120Fluorouracil 90Cetuximab 84Leucovorin 82Oxaliplatin 80pembrolizumab 70Irinotecan 66Nivolumab 46Capecitabine 43Specimen Handling 40regorafenib 30Folfox protocol 29trifluridine tipiracil drug combination 28Magnetic Resonance Spectroscopy 27Biopsy 27Panitumumab 26HMPL-013 26Standard of Care 25IFL protocol 21Gemcitabine 20Blood Specimen Collection 19tislelizumab 18atezolizumab 18Trifluridine 18Cisplatin 18balstilimab 16Colonoscopy 16Carboplatin 16encorafenib 15Paclitaxel 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Antibodies × 1 year × Clear all
NCT06451497 2026-04-02

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Zumutor Biologics Inc.

Phase 1 Recruiting
100 enrolled
BreastGastrointestinalGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

NCT00199862 2025-07-04

Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer

Memorial Sloan Kettering Cancer Center

Phase NA Completed
30 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡